Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Atea Pharmaceuticals excels in Q3 with promising HCV program

Atea Pharmaceuticals demonstrated strong performance in Q3 2024, with promising trial results and a solid financial position.
The company's HCV program shows great potential for addressing unmet medical needs and driving future growth.
While facing challenges in trial design and market competition, Atea remains confident in its ability to innovate and succeed in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea together with other members of the Atea management team, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 p.m. ET.

Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19.  Roche Holding AG (OTC: RHHBY) and Atea jointly develop AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform.

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY) of $50 million. Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19.

Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche

Milestone in the amount of $50 million realized Milestone in the amount of $50 million realized

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences.

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET.

Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Former U.S. Surgeon General Brings Wealth of Clinical and Public Health Experience Former U.S. Surgeon General Brings Wealth of Clinical and Public Health Experience

Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

Atea Pharmaceuticals, Inc.'s (AVIR) CEO Jean-Pierre Sommadossi on Q1 2021 Results - Earnings Call Transcript

Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Atea Pharmaceuticals (AVIR) Enters Oversold Territory

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2021, and to provide a corporate update.

Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial anticipates enrolling approximately 1,400 non-hospitalized adults and adolescents with mild to moderate COVID-19.

Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing

Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Atea Pharmaceuticals (AVIR) has been struggling lately, but the selling pressure may be coming to an end soon

Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?

Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?

– Rapid advancement of AT-527 for COVID-19 –

Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2020, and to provide a business overview.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

Coherent Corp

Criteo

Diamondback Energy

Sleep Number

As the Nasdaq eroded all the gains made this year and turned red due to the tech sell-off, there are still some stocks that have gained more than 50% so far this year.

Nasdaq Turns Red YTD: 5 Top-Ranked Stocks Up More Than 50%

ADMA Biologics

BioNTech SE

Lexicon Pharmaceuticals

Moderna

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19 Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Johnson & Johnson

Legend Biotech

Eli Lilly

Nkarta, Inc.

Roche Holding AG

Avidity Biosciences

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Biotech Shares Have Soared Since 2020's Wave of IPOs

Data underscore key mechanistic features enabling AT-527 to inhibit SARS-CoV-2 viral replication and support current late-stage clinical development program Data underscore key mechanistic features enabling AT-527 to inhibit SARS-CoV-2 viral replication and support current late-stage clinical development program

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19 Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

RedHill Biopharma

This could be a key year for these companies' treatment candidates.

These 2 Coronavirus Stocks Could Soar in the First Half of 2021

Atea has a major deal with Roche. Atea just IPO-ed, but it already has $4.4bn in market cap.

News for Atea Pharmaceuticals Stock (AVIR)